Novartis Slump and Energy Spike Keep European Markets on Edge

Brent crude surged toward $98 a barrel Tuesday following Houthi strikes on Saudi energy infrastructure, forcing European investors to balance volatile energy gains against the broader threat of regional instability and the sudden, sharp decline of pharmaceutical giant Novartis after a critical drug trial failure.

Editorial·September 8, 2026·reads: 1,285

Novartis Slump and Energy Spike Keep European Markets on Edge

Novartis shares suffered their steepest single-day drop in recent memory, reeling from the collapse of a late-stage clinical trial for a muscle-wasting disorder treatment. This setback overshadowed the resilience of energy and mining sectors, which benefited from the climb in commodity prices. Copper producers Boliden, Antofagasta, and KGHM saw their valuations rise alongside the price of the metal.

The broader economic outlook remains clouded by a surprise dip in German exports during July, signaling fragility in the European trade recovery. With oil prices pushing inflation fears to the forefront, bond markets reacted with a global selloff. Investors are now looking toward the European Central Bank for potential rate hikes, while monitoring upcoming U.S. inflation data that could dictate the Federal Reserve's next policy move.